Born in Glencoe, Illinois, on November 23, 1953, Carl began his work with prostaglandins as an undergraduate majoring in biochemistry at Yale University. He discovered that, in contrast to what was believed at the time, prostaglandins can lower intraocular pressure if given in low concentrations. In medical school at Columbia University, with convincing data and much perseverance, Camras persuaded one of his professors to take on the prostaglandin project. In collaboration with many others, the topical prostaglandin F2α analogue latanoprost was developed. First approved in 1996, the prostaglandin analogues are now the most widely prescribed glaucoma medications in the world.